OMS-405 is under clinical development by Omeros and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect OMS-405’s likelihood of approval (LoA) and phase transition for Opium (Opioid) Addiction took place on 02 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OMS-405 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

OMS-405 overview

OMS-405 (OMS-403) is under development for the treatment of opioid, nicotine addiction and cocaine abuse. The drug candidate acts by targeting peroxisome proliferator-activated gamma receptor (PPARgamma). It was under development for the treatment of alcohol addiction.

Omeros overview

Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Quick View OMS-405 LOA Data

Report Segments
  • Innovator
Drug Name
  • OMS-405
Administration Pathway
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Omeros
  • Originator: Universita degli Studi di Camerino
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.